From a clinical standpoint, the fact that PDE6D inhibition efficiently triggered an antileukemic response in AKT dependent cell lines independently of their RAS mutational status, emphasizes the importance of studying pathway dependency in cancer cells rather than focusing on their mutational landscape when deciding which inhibitors to use. The gene discussed is PDE6D; the disease is cancer.